Home - Chinese Journal of Cancer Research

2021 Impact Factor of CJCR: 4.026
Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common in tumor-related mortality by Global Cancer Statistics 2020. Recent data show that the incidence and mortality of CRC in China are increasing, with the number of new cases and deaths reaching 607,900 and 261,777 in 2019. The Chinese Society of Clinical Oncology (CSCO) published the first version guidelines in April 2017 and updated annually according to the latest clinical data and the changes in China’s national conditions. Here we present the main updates of the 2022 version compared with the previous version.

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Lymphomas are a group of heterogeneous diseases, which is divided into two main categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). There is an estimated 75,400 incidence cases and 40,500 deaths annually in China, of which NHL accounts for about 90% of lymphoma burden.

Attributable deaths of liver cancer in China

Liver cancer is the sixth most commonly diagnosed cancer and the third cancer-related death worldwide, with 905,677 cases and 830,180 deaths in 2020. Of these, nearly 45.3% of new cases and 47.1% of deaths occurred in China. Several epidemiological studies have identified several risk factors associated with liver cancer, including chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), alcohol consumption, tobacco use, metabolic diseases such as obesity and diabetes. Of which, HBV and HCV, primary risk factors for liver cancer in China, have contributed to the most substantial proportion of liver cancer burden in China. Studies have also shown that liver cancer burden varies significantly across regions and sex due to the heterogeneous exposure of risk factors. In this study provide detailed results of the liver cancer burden in the Chinese population attributable to HBV, HCV, diabetes, excess bodyweight, alcohol drinking, tobacco smoking, and Clonorchis sinensis in 2014 stratified by age groups, sex, and provinces. HBV still contributes to the majority of liver cancer burden than any other risk factors.

‹ ›

Vol 34, No 6 (December 2022)

Review Article

Stomach cancer burden in China: Epidemiology and prevention

Xinxin Yan, Lin Lei, He Li, Maomao Cao, Fan Yang, Siyi He, Shaoli Zhang, Yi Teng, Qianru Li, Changfa Xia, Wanqing Chen

Pages: 81-91 HTML

When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road

Yufeng Gu, Shengjun Xu, Zhengxin Wang, Jiayin Yang, Shusen Zheng, Qiang Wei, Zhikun Liu, Xiao Xu

Pages: 92-107 HTML

Transforming cancer cells for long-term living with cancer: An inspiring new approach

Mingjie Jiang, Dianna Gu, Furao Liu, Chenjing Lin, Ling Tian

Pages: 108-125 HTML

Original Article

Integrated strategies for chemotherapy cycles in nasopharyngeal carcinoma patients: Real-world data from two epidemic centers guiding decision-making

Zejiang Zhan, Yingying Huang, Jiayu Zhou, Zhuochen Cai, Haoyang Huang, Ying Deng, Wenze Qiu, Xun Cao, Xi Chen, Chixiong Liang, Lulu Zhang, Xiang Guo, Taize Yuan, Xing Lyu

Pages: 126-139 HTML

Variant rs8400 enhances ALKBH5 expression through disrupting miR-186 binding and promotes neuroblastoma progression

Qian Guan, Huiran Lin, Wenfeng Hua, Lei Lin, Jiabin Liu, Linqing Deng, Jiao Zhang, Jiwen Cheng, Zhonghua Yang, Yong Li, Jun Bian, Haixia Zhou, Suhong Li, Li Li, Lei Miao, Huimin Xia, Jing He, Zhenjian Zhuo

Pages: 140-162 HTML

Exploration and optimization of surgical techniques for laparoscopic transhiatal lower mediastinal lymph node dissection for adenocarcinoma of esophagogastric junction: A prospective IDEAL 2a study with qualitative design

Yinkui Wang, Fanling Hong, Shuangxi Li, Fei Shan, Yongning Jia, Rulin Miao, Zhemin Li, Ziyu Li, Jiafu Ji

Pages: 163-175 HTML

Aqueous-soluble components of sporoderm-removed Ganoderma lucidum spore powder promote ferroptosis in oral squamous cell carcinoma

Xiangping Wu, Qingnan Wu, Yan Wang, Yehai Liu, Zhenhao Li, Qingchuan Liu, Zhengming Huang, Mingyan Li, Bin Zhang, Qimin Zhan

Pages: 176-190 HTML

Perspective

Adjuvant therapy for hormone receptor-positive breast cancer: Perspective from a survey on breast cancer physicians’ acceptance of practice-changing data

Asian Institute of Clinical Oncology (AICO) Expert Panel

Pages: 191-196 HTML

Guidelines

Management guidelines for preventing exposure to antineoplastics

Wei Liu, Ziyang Wu, Tong Sun, Shuyao Liang, Jun Zhu, Suodi Zhai, Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society, Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association, Oncology Society of Chinese Medical Association, Nursing Branch of China International Exchange and Promotive Association for Medical and Healthcare, Division of Drug-induced Diseases of Chinese Pharmacology Society

Pages: 1-10 HTML

NHCPRC Guidelines

National guidelines for diagnosis and treatment of malignant lymphoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 425-446 HTML

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 309-334 HTML

National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 335-342 HTML

National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 131-150 HTML

National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 151-175 HTML

National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 176-206 HTML

National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 207-237 HTML

National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 238-255 HTML

National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 256-269 HTML

National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 270-288 HTML

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Caixia Dong, Yuwei Ding, Shanshan Weng, Guichao Li, Yanqing Huang, Hanguang Hu, Zhen Zhang, Suzhan Zhang, Ying Yuan

Pages: 302-307 HTML

National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 415-445 HTML

Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 707-737 HTML

Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 578-585 HTML

Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 557-577 HTML

Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 223-258 HTML

Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 259-277 HTML

Chinese guidelines for diagnosis and treatment of pancreatic cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 278-294 HTML

Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 295-305 HTML

Chinese guidelines for diagnosis and treatment of primary lung cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 1-28 HTML

Chinese guidelines for diagnosis and treatment of renal cell carcinoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 29-48 HTML

Chinese guidelines for diagnosis and treatment of urothelial carcinoma of bladder 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 49-66 HTML

Chinese guidelines for diagnosis and treatment of prostate cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 67-83 HTML

CSCO Guidelines

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Zhijun Yuan, Shanshan Weng, Chenyang Ye, Hanguang Hu, Suzhan Zhang, Ying Yuan

Pages: 67-70 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Jun Zhu, Jun Ma, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology

Pages: 289-301 HTML

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018

Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 423-425 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group

Pages: 84-98 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group

Pages: 99-116 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group

2021 Impact Factor of CJCR: 4.026Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Attributable deaths of liver cancer in China

About cjcr

Advertising

Contact us

Review Article

Original Article

Perspective

Guidelines

NHCPRC Guidelines

CSCO Guidelines

Virtual Special Issues

Beijing Cancer Hospital

China Anti-cancer Association

Chronic Diseases and Translational Medicine

2018 CGCC

2021 Impact Factor of CJCR: 4.026
Journal Citation Reports®, Clarivate Analytics